Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

Volker Heinemann; Ursula Vehling-Kaiser; Dirk Waldschmidt; Erika Kettner; Angela Märten; Cornelia Winkelmann; Stefan Klein; Georgi Kojouharoff; Thomas C Gauler; Ludwig Fischer von Weikersthal; Michael R Clemens; Michael Geissler; Tim F Greten; Susanna Hegewisch-Becker; Oleg Rubanov; Gerold Baake; Thomas Höhler; Yon D Ko; Andreas Jung; Sascha Neugebauer; Stefan Boeck

doi:10.1136/gutjnl-2012-302759

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Hosted content
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

Pancreas

Original article

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password